# New Peptide Vaccines for Fighting Cancer

> This patent describes new protein fragments, called polypeptides, designed to help the body's immune system fight specific cancers like lung, stomach, and skin cancer.

- **Patent:** US 12734225
- **Original title:** Fusion peptide vaccines
- **Granted:** 2026
- **Status:** Active
- **Times cited:** 0
- **Field:** biotech, pharmaceutical, medical_devices

## What it does

The patent covers specific protein pieces, or polypeptides, that are designed to trigger a strong immune response against cancer cells. These peptides contain parts, known as T cell epitopes, that are recognized by the immune system's T cells. The goal is to teach the T cells to attack and destroy cancer cells, particularly in cancers like gastric cancer, lung cancer, melanoma, and bladder cancer. The patent also mentions using these peptides in pharmaceutical compositions, meaning they are formulated into medicines, and suggests methods for identifying patients who would benefit most from this treatment.

## What it does NOT cover

- Does not cover vaccines for infectious diseases like the flu or COVID-19.
- Does not cover general cancer treatments that don't use specific T cell epitopes.
- Does not cover diagnostic methods unrelated to identifying patients for peptide vaccine treatment.
- Does not cover the use of whole proteins or DNA/RNA in the vaccine formulation.
- Does not cover treatments for cancers not listed in the patent, such as brain tumors or leukemia.

## The clever bit

The key innovation lies in identifying specific T cell epitopes within fusion peptides that are highly immunogenic, meaning they reliably provoke a strong immune response across a large percentage of patients, making the vaccine potentially more effective for a broader population.

## Real-world examples

1. Potential cancer vaccines for lung cancer
2. Potential cancer vaccines for melanoma
3. Potential cancer vaccines for gastric cancer
4. Potential cancer vaccines for bladder cancer

## Why it matters

Developing new ways to harness the immune system to fight cancer is a major focus in medicine. This patent represents a specific approach to cancer immunotherapy, aiming to create vaccines that are effective against a range of common and difficult-to-treat cancers.

## Frequently asked questions

### What does New Peptide Vaccines for Fighting Cancer cover?

This patent describes new protein fragments, called polypeptides, designed to help the body's immune system fight specific cancers like lung, stomach, and skin cancer.

### When does this patent expire?

This patent is expected to expire on September 15, 2046, when the invention enters the public domain.

### What problem does this patent solve?

Developing new ways to harness the immune system to fight cancer is a major focus in medicine. This patent represents a specific approach to cancer immunotherapy, aiming to create vaccines that are effective against a range of common and difficult-to-treat cancers.

### What does this patent NOT cover?

Does not cover vaccines for infectious diseases like the flu or COVID-19.

**Full plain-English explainer:** https://patentbrief.org/patent/us/12734225/fusion-peptide-vaccines

**Original patent:** https://patents.google.com/patent/US12734225

---

_Source: PatentBrief — https://patentbrief.org. Patent facts are from public records; the plain-English explanation is PatentBrief's._